NCT03120000View on ClinicalTrials.gov

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

PQR309

Oral PQR309, 80mg or 60mg daily or intermittent dosing

Trial Locations (4)

13305

Aix-Marseilles Université, Marseille

44800

Hématologie, Départment d'ongolgie médicale, Saint-Herblain

54035

Service de Neurology CHRU de Nancy, Nancy

75013

Hôpital Pitié-Sâlpétrier,, Paris

Sponsors
All Listed Sponsors
lead

PIQUR Therapeutics AG

INDUSTRY